This Plain Language Summary of Publication article from Future Oncology looks at a medicine called talquetamab. A study called MonumenTAL-1 evaluated how safe the medication was, at different doses, to treat people with multiple myeloma (a type of blood cancer) who did not respond (refractory), stopped responding (relapsed), or who had difficulty dealing with their previous treatments.
Read the full article here.
The original article on which this summary is based was published in the New England Journal of Medicine. The article is called ‘Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma’.
Read the original article here.